|
|
|
||
Re: BLUE A best in breed “genome medicine” nameWhen Celgene takes an equity position in another company, it participates fully in all of that company's product outcomes to the extent that the company's stock price increases, not just the ones that it has agreed to commercially develop and market for or with the company. I think that the analysts are missing that reality, "big time". JMHO. |
return to message board, top of board |